| Indicators | Browse All

Pluri Inc. (PLUR)

Healthcare | Biotechnology | Haifa, Israel | NasdaqCM
1.53 USD
After hours: 1.53

Short-term:★☆☆☆☆Long-term:⯪☆☆☆☆Dividends:☆☆☆☆☆
Hot Take | Aug. 22, 2026, 2:54 a.m. EDT

The immediate outlook is severely clouded by a negative statistical forecast leaning down over the next 45 days, compounded by a recent price pattern that failed to sustain gains after a brief rally. While the stock recently climbed from mid-August lows, it has since retreated, trading well below its 50-day moving average, which suggests the immediate momentum is exhausted rather than building. The fundamental picture is dire for any long-term holder: the company is burning through cash at an alarming rate with negative free cash flow and operating losses, while revenue has collapsed by nearly 60% year-over-year. The balance sheet is fragile, with debt significantly outweighing cash reserves and a current ratio indicating severe liquidity stress. Although the latest annual report shows a technical recovery in price compared to the prior year, the broader nine-year trajectory remains a catastrophic decline of over 95%, erasing almost all historical value. There is no dividend to provide income, and the valuation metrics, including a negative book value and negative earnings per share, reflect a business in distress rather than a deep-value opportunity. The combination of deteriorating fundamentals, shrinking revenues, and weak technical structure makes this a high-risk speculative vehicle unsuitable for investment.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoTheta ✓0.093093
MSTL0.187728
AutoARIMA0.195653
AutoETS0.195655

Forecast horizon: 45 days | Selected: AutoTheta

Forecast Reliability
Score 34%
H-stat 14.05
Ljung-Box p 0.000
Jarque-Bera p 0.154
Excess Kurtosis -1.13
Attribute Value
Sector Healthcare
Revenue per Share 0.12
Market Cap 16,508,005
Forward P/E -0.81
Beta 0.68
Website https://www.pluri-biotech.com

Info Dump

Attribute Value
52 Week Change -0.6909091
Address1 MATAM Advanced Technology Park
Address2 Building No. 5
All Time High 30,400.0
All Time Low 1.45
Ask 1.61
Ask Size 1
Average Daily Volume10 Day 37,080
Average Daily Volume3 Month 29,053
Average Volume 29,053
Average Volume10Days 37,080
Beta 0.678
Bid 1.57
Bid Size 3
Book Value -1.783
City Haifa
Compensation As Of Epoch Date 1,767,139,200
Country Israel
Crypto Tradeable 0
Currency USD
Current Price 1.53
Current Ratio 0.327
Custom Price Alert Confidence HIGH
Date Short Interest 1,786,665,600
Day High 1.6289
Day Low 1.46
Display Name Pluri
Dividend Date 1,564,012,800
Earnings Timestamp End 1,758,571,200
Earnings Timestamp Start 1,758,052,800
Ebitda -25,515,000
Ebitda Margins 0.0
Enterprise To Ebitda -1.819
Enterprise To Revenue 43.019
Enterprise Value 46,418,004
Eps Forward -1.9
Eps Trailing Twelve Months -2.79
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 1.8082
Fifty Day Average Change -0.27820003
Fifty Day Average Change Percent -0.15385468
Fifty Two Week Change Percent -69.09091
Fifty Two Week High 5.29
Fifty Two Week High Change -3.76
Fifty Two Week High Change Percent -0.7107751
Fifty Two Week Low 1.45
Fifty Two Week Low Change 0.07999992
Fifty Two Week Low Change Percent 0.055172358
Fifty Two Week Range 1.45 - 5.29
Financial Currency USD
First Trade Date Milliseconds 1,056,979,800,000
Float Shares 4,442,488
Forward Eps -1.9
Forward P E -0.80526316
Free Cashflow -14,668,375
Full Exchange Name NasdaqCM
Full Time Employees 127
Fullday Change 0.0
Fullday Change Percent 0.0
Fullday Price 1.53
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.43003
Gross Profits 464,000
Has Pre Post Market Data 1
Held Percent Insiders 0.48238
Held Percent Institutions 0.12543
Implied Shares Outstanding 10,789,546
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,751,241,600
Last Split Date 1,711,929,600
Last Split Factor 1:8
Long Business Summary Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and immunotherapy platform. Its product candidates include PLX-PAD, that is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle injuries following hip fracture, acute respiratory distress syndrome due to coronavirus Disease (COVID-19), peripheral artery disease, intermittent claudication, and critical limb ischemia; PLX-R18, composed of fetal MSC like cells originating from the placenta for the treatment of hematopoietic complications of the H-ARS, and is in Phase I clinical trial to treat hematopoietic cell transplantation; and allogeneic MAIT cell therapy platform. The company also offers cell manufacturing services and cell-based coffee; and develops and commercializes cultivated meat products. It operates in the field of regenerative medicine, food tech, immunotherapy, CDMO, and AgTech. It has collaboration agreement with Bar-Ilan University to advance cancer immunotherapy for solid tumors. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
Long Name Pluri Inc.
Market us_market
Market Cap 16,508,005
Market State CLOSED
Max Age 86,400
Message Board Id finmb_6124664
Most Recent Quarter 1,774,915,200
Net Income To Common -25,539,000
Next Fiscal Year End 1,782,777,600
Non Diluted Market Cap 16,508,005
Open 1.52
Operating Cashflow -20,361,000
Operating Margins -39.13772
Payout Ratio 0.0
Phone 972 74 710 8600
Post Market Change 0.0
Post Market Change Percent 0.0
Post Market Price 1.53
Post Market Time 1,787,947,804
Previous Close 1.53
Price Hint 4
Price To Book -0.8581043
Price To Sales Trailing12 Months 15.2993555
Profit Margins 0.0
Quick Ratio 0.294
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change 0.0
Regular Market Change Percent 0.0
Regular Market Day High 1.6289
Regular Market Day Low 1.46
Regular Market Day Range 1.46 - 1.6289
Regular Market Open 1.52
Regular Market Previous Close 1.53
Regular Market Price 1.53
Regular Market Time 1,787,947,200
Regular Market Volume 24,332
Return On Assets -0.51236
Revenue Growth -0.609
Revenue Per Share 0.12
Sand P52 Week Change 0.20504117
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 10,789,546
Shares Percent Shares Out 0.0014
Shares Short 15,514
Shares Short Previous Month Date 1,784,073,600
Shares Short Prior Month 23,989
Short Name Pluri Inc.
Short Percent Of Float 0.0077
Short Ratio 0.64
Source Interval 15
Symbol PLUR
Total Cash 9,322,000
Total Cash Per Share 0.864
Total Debt 33,628,000
Total Revenue 1,079,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -2.79
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 2.8937
Two Hundred Day Average Change -1.3636999
Two Hundred Day Average Change Percent -0.47126514
Type Disp Equity
Volume 24,332
Website https://www.pluri-biotech.com
Zip 3,508,409